Research programme: botulism vaccines - DynPort Vaccine Company
Latest Information Update: 03 Apr 2008
At a glance
- Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
- Developer Cambridge Biostability; DynPort Vaccine Company
- Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Botulism
Most Recent Events
- 03 Apr 2008 Preclinical development of a vaccine against seven botulinum neurotoxins is ongoing